AU2016233143B2 - Methods for the treatment of bladder cancer - Google Patents

Methods for the treatment of bladder cancer Download PDF

Info

Publication number
AU2016233143B2
AU2016233143B2 AU2016233143A AU2016233143A AU2016233143B2 AU 2016233143 B2 AU2016233143 B2 AU 2016233143B2 AU 2016233143 A AU2016233143 A AU 2016233143A AU 2016233143 A AU2016233143 A AU 2016233143A AU 2016233143 B2 AU2016233143 B2 AU 2016233143B2
Authority
AU
Australia
Prior art keywords
mitomycin
prodrug
liposomal
bladder cancer
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016233143A
Other languages
English (en)
Other versions
AU2016233143A1 (en
Inventor
Alberto Gabizon
Patricia OHANA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipomedix Pharmaceuticals Ltd
Original Assignee
Lipomedix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipomedix Pharmaceuticals Ltd filed Critical Lipomedix Pharmaceuticals Ltd
Publication of AU2016233143A1 publication Critical patent/AU2016233143A1/en
Application granted granted Critical
Publication of AU2016233143B2 publication Critical patent/AU2016233143B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016233143A 2015-03-17 2016-03-17 Methods for the treatment of bladder cancer Ceased AU2016233143B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134328P 2015-03-17 2015-03-17
US62/134,328 2015-03-17
PCT/US2016/022909 WO2016149516A1 (en) 2015-03-17 2016-03-17 Methods for the treatment of bladder cancer

Publications (2)

Publication Number Publication Date
AU2016233143A1 AU2016233143A1 (en) 2017-10-19
AU2016233143B2 true AU2016233143B2 (en) 2021-03-25

Family

ID=56919480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016233143A Ceased AU2016233143B2 (en) 2015-03-17 2016-03-17 Methods for the treatment of bladder cancer

Country Status (6)

Country Link
US (1) US20180071253A1 (enExample)
EP (1) EP3270898B1 (enExample)
JP (2) JP6859275B2 (enExample)
AU (1) AU2016233143B2 (enExample)
CA (1) CA2985330A1 (enExample)
WO (1) WO2016149516A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3126211A1 (en) * 2019-01-11 2020-07-16 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161455A1 (en) * 1999-04-23 2004-08-19 Alza Corporation Method for treating multi-drug resistant tumors
US20050165227A1 (en) * 2002-05-15 2005-07-28 Vlahov Iontcho R. Vitamin-mitomycin conjugates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
WO1998007409A1 (en) 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
EP1880736A1 (en) 1999-04-23 2008-01-23 Alza Corporation Releasable linkage and composition containing same
WO2015191576A1 (en) * 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161455A1 (en) * 1999-04-23 2004-08-19 Alza Corporation Method for treating multi-drug resistant tumors
US20050165227A1 (en) * 2002-05-15 2005-07-28 Vlahov Iontcho R. Vitamin-mitomycin conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GABIZON, A. et al. "Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates" Advanced Drug Delivery Reviews (2004) Vol.56 No.8, pages 1177 to 1192 *

Also Published As

Publication number Publication date
AU2016233143A1 (en) 2017-10-19
EP3270898A4 (en) 2018-10-31
JP6859275B2 (ja) 2021-04-14
JP2021035973A (ja) 2021-03-04
WO2016149516A1 (en) 2016-09-22
US20180071253A1 (en) 2018-03-15
JP2018508589A (ja) 2018-03-29
CA2985330A1 (en) 2016-09-22
EP3270898A1 (en) 2018-01-24
EP3270898B1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
KR100889139B1 (ko) 이리노테칸 제제
Hossann et al. In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes
ES2333400T3 (es) Composiciones y procedimientos para tratar linfonas.
US20170273906A1 (en) Targeted liposomes encapsulating iron complexes and their uses
JP2004525138A (ja) 治療剤の改良された細胞内送達のためのリポソーム組成物
JPH11513392A (ja) ミトザントロンのリポソーム製剤
EP2190411A2 (en) Liposome compositions for in vivo administration of boronic acid compounds
KR101925507B1 (ko) 조절 약물 방출 리포솜 조성물
US20080026049A1 (en) Liposomal compositions for parenteral delivery of agents
JP2018505224A (ja) ナノ粒子を含む組成物並びに腫瘍を治療する方法
US20030082228A1 (en) Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US20240173257A1 (en) Liposome formulations
JP2003522193A (ja) ホスホリパーゼａ２で分解可能な脂質誘導体を含有する脂質をベースとした薬物送達系、および治療におけるその使用
AU2016233143B2 (en) Methods for the treatment of bladder cancer
Hao et al. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan
JP4874097B2 (ja) 水難溶性カンプトテシン含有リポソーム製剤
WO2000009071A2 (en) A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
JP2022551311A (ja) 活性剤の沈殿物を含む送達系複合体および使用方法
Messerer Liposomal encapsulation of irinotecan and potential for the use of liposomal drug in the treatment of liver metastases associated with advanced colorectal cancer
US20250268827A1 (en) Combined medicinal drug including liposome composition encompassing topotecan or salt thereof and dna damage repair inhibitor
KR20240037264A (ko) Bcl 억제제의 리포솜 제형
Woo Thermosensitive liposomal cisplatin: formulation development, in vitro characterization and in vivo plasma elimination studies
JP2003221336A (ja) 抗悪性腫瘍剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired